Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Reducing Mortality Due to Cervical Cancer

Reducing Mortality Due to Cervical Cancer EDITORIAL PAPNET Fails the Test INCE ITS INTRODUCTION into clinical prac- The past 20 years have brought the introduction of tice in the 1940s, the Papanicolaou smear many technologies that have attempted to improve the has become one of the most notable suc- diagnosis of cervical cancer and its precursors. These cess stories in preventive screening. The have included colposcopy, cervicography, speculo- S overall impact of regular screening in an scopy, new cytologic sampling instruments (Cytobrush, organized program is a reduction of the number of Cervex Brush), new methods for processing the cyto- women in whom invasive cervical cancer develops of logic sample (Thinprep; Cytec, Boxborough, Mass), and up to 90%. methods for review of cytologic interpretation Despite this success, concerns remain about the (PAPNET [Neuromedical Systems, Incorporated, Suf- weaknesses inherent in Papanicolaou smear testing. fern, NY], Neopath [Redmond, Wash]). Many of these The weakness of greatest concern to clinicians and tests, including PAPNET, have been designed speci- women is the potential for a false-negative result. fically to reduce the rate of false-negative results. Sources of a false-negative result include failure of the PAPNET, based on computerized imaging and neural clinician to obtain an adequate sample, failure of the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Family Medicine American Medical Association

Reducing Mortality Due to Cervical Cancer

Melnikow, Joy; Nuovo, James
Archives of Family Medicine , Volume 8 (1) – Jan 1, 1999
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/reducing-mortality-due-to-cervical-cancer-gHE0x6bdbk
Publisher
American Medical Association
Copyright
Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
1063-3987
eISSN
1063-3987
DOI
10-1001/pubs.Arch Fam Med.-ISSN-1063-3987-8-1-fed8003
Publisher site

Abstract

EDITORIAL PAPNET Fails the Test INCE ITS INTRODUCTION into clinical prac- The past 20 years have brought the introduction of tice in the 1940s, the Papanicolaou smear many technologies that have attempted to improve the has become one of the most notable suc- diagnosis of cervical cancer and its precursors. These cess stories in preventive screening. The have included colposcopy, cervicography, speculo- S overall impact of regular screening in an scopy, new cytologic sampling instruments (Cytobrush, organized program is a reduction of the number of Cervex Brush), new methods for processing the cyto- women in whom invasive cervical cancer develops of logic sample (Thinprep; Cytec, Boxborough, Mass), and up to 90%. methods for review of cytologic interpretation Despite this success, concerns remain about the (PAPNET [Neuromedical Systems, Incorporated, Suf- weaknesses inherent in Papanicolaou smear testing. fern, NY], Neopath [Redmond, Wash]). Many of these The weakness of greatest concern to clinicians and tests, including PAPNET, have been designed speci- women is the potential for a false-negative result. fically to reduce the rate of false-negative results. Sources of a false-negative result include failure of the PAPNET, based on computerized imaging and neural clinician to obtain an adequate sample, failure of the

Journal

Archives of Family Medicine – American Medical Association

Published: Jan 1, 1999

References

  • Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies.
  • The effect of different sampling devices on the presence of endocervical cells in cervical smears: a meta-analysis.
    Buntinx, F; Essed, GGM; Knottnerus, JA; Crebolder, HFJM
  • Relation between sampling device and detection of abnormality in cervical smears: a meta-analysis of randomised and quasi-randomised studies.
    Buntinx, F; Brouwers, M
  • Effect of the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) on the incidence of invasive cervical cancer.
    Helfand, M; O'Connor, GT; Zimmer-Gembeck, M; Beck, JR
  • The 1988 Bethesda system for reporting cervical/vaginal cytological diagnoses.
  • Quality assurance in cervical cytology: the Papanicolaou smear.
  • Costs and outcomes of PAPNET secondary screening technology for cervical cytologic evaluation: a community hospital's experience.
    Brotzman, GL; Kretzchmar, S; Ferguson, D; Gottlieb, M; Stowe, C
  • PAPNET-assisted rescreening of cervical smears: cost and accuracy compared with a 100% manual rescreening strategy.
    O'Leary, TJ; Tellado, M; Buckner, SB; Ali, IS; Stevens, A; Ollayos, CW
  • Clinical Epidemiology.
    Sackett, DL; Haynes, RB; Guyatt, GH; Tugwell, P
  • Failure of extracranial-intracranial bypass to reduce the risk of ischemic stroke: results of an international randomized trial.
  • Healthy People 2000 at mid decade.
    McGinnis, JM; Lee, PR
  • Demographic predictors of mammography and Pap smear screening in US women.
    Calle, EE; Flanders, D; Thun, M; Martin, LM
  • Improving the follow-up of patients with abnormal Papanicolaou smear results.
    McKee, D